Ignite Creation Date:
2024-05-05 @ 5:14 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00415038
Status:
COMPLETED
Last Update Posted:
2011-06-17
First Post:
2006-12-21
Brief Title:
Efficacy of Rostafuroxin in the Treatment of Essential Hypertension
Sponsor:
sigma-tau ifr SpA
Organization:
sigma-tau ifr SpA
Study Overview
Official Title:
A Double Blind Dose Range Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable Uncomplicated Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2011-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of this population in which genetic patterns could be involved in the etiology of essential hypertension
Detailed Description:
Elevated arterial pressure is probably the most important public health problem about 30 of the world adult population are affected by hypertension in industrialised countries Development of a pharmacogenomic approach to the therapy of primary hypertension give new opportunities for the treatment of hypertension This approach consists in the identification of the genetic-molecular mechanisms responsible for hypertension in a given subset of patients and in the development of drugs able to interfere with such mechanisms thus leading to very selective therapeutic interventions with enhanced efficacy and reduced side effects
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None